Lisaftoclax

A Global Multicenter, Double-blind, Randomized, Registrational Phase 3 Study of Lisaftoclax (APG-2575) in Combination With Azacitidine (AZA) in Patients With Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS) (GLORA-4).

More Information

Trial Status
Not yet accepting
Trial Phase
Phase 3
Enrollment
464 patients (estimated)
Sponsors
Ascentage Pharma Group Inc.
Tags
BCL-2 Inhibitor, Placebo, Randomization
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
2010
NCT Identifier
NCT06641414

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.